AIDS:服用五种或以上处方药会增加艾滋病风险

2018-02-01 榕榕 来宝网

HIV

服用五种或五种以上处方药会增加感染艾滋病病毒的老年人和无艾滋病毒的成人的住院和死亡风险。这项由耶鲁大学牵头的研究结果突出了为多种疾病患者开具额外药物的潜在风险。

服用多种处方药会增加患有HIV的成年人的风险】服用五种或五种以上处方药会增加感染艾滋病病毒的老年人和无艾滋病毒的成人的住院和死亡风险。这项由耶鲁大学牵头的研究结果突出了为多种疾病患者开具额外药物的潜在风险。

这项研究发表在艾滋病杂志上。

多种药物的使用被称为多药,这是一个共同的问题,为药物相互作用明显增加以及使用不适当的药物。然而,在普通人群中进行的研究很少,而且之前没有在艾滋病毒感染者中进行过研究,他们已经研究了与多药性相关的实际健康结果。

使用退伍军人老龄队列研究的患者数据,主要作者医学博士Amy Justice及其同事分析了2009年至少接受过一次VA治疗的HIV阳性和未感染患者的结果。由于HIV患者必须服用至少三种抗逆转录病毒药物治疗艾滋病毒感染,研究人员集中在非ARV处方。他们跟踪了平均五十岁以上的病人平均六年。

研究小组发现,非抗逆转录病毒药物在有或没有感染艾滋病病毒的成年人中很常见。最初不清楚的是患者是否因为病情较重而服用更多的药物,或者服用更多的药物会使他们病情加重。研究人员在调整了患者疾病的严重程度之后,发现多药治疗仍然与住院和死亡有关。值得注意的是,处方剂量越多,两组患者的风险越大,研究人员说。

研究人员指出,虽然该研究没有把重点放在风险增加背后的原因上,但毒性,副作用和药物相互作用等因素可能是导致风险增加的原因。

原始出处:

Amy C. Justice et al. Non antiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals, AIDS (2018). DOI: 10.1097/QAD.0000000000001756.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2033862, encodeId=edbe2033862a7, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 24 15:21:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285562, encodeId=8f3928556242, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Feb 06 07:07:17 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365638, encodeId=72c913656380b, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Feb 03 00:21:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284441, encodeId=922c284441ed, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Fri Feb 02 10:25:45 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284416, encodeId=5eef284416c4, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Feb 02 08:17:25 CST 2018, time=2018-02-02, status=1, ipAttribution=)]
    2018-05-24 wjywjy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2033862, encodeId=edbe2033862a7, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 24 15:21:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285562, encodeId=8f3928556242, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Feb 06 07:07:17 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365638, encodeId=72c913656380b, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Feb 03 00:21:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284441, encodeId=922c284441ed, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Fri Feb 02 10:25:45 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284416, encodeId=5eef284416c4, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Feb 02 08:17:25 CST 2018, time=2018-02-02, status=1, ipAttribution=)]
    2018-02-06 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2033862, encodeId=edbe2033862a7, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 24 15:21:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285562, encodeId=8f3928556242, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Feb 06 07:07:17 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365638, encodeId=72c913656380b, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Feb 03 00:21:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284441, encodeId=922c284441ed, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Fri Feb 02 10:25:45 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284416, encodeId=5eef284416c4, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Feb 02 08:17:25 CST 2018, time=2018-02-02, status=1, ipAttribution=)]
    2018-02-03 cooco
  4. [GetPortalCommentsPageByObjectIdResponse(id=2033862, encodeId=edbe2033862a7, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 24 15:21:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285562, encodeId=8f3928556242, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Feb 06 07:07:17 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365638, encodeId=72c913656380b, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Feb 03 00:21:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284441, encodeId=922c284441ed, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Fri Feb 02 10:25:45 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284416, encodeId=5eef284416c4, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Feb 02 08:17:25 CST 2018, time=2018-02-02, status=1, ipAttribution=)]
    2018-02-02 戒馋,懒,贪

    谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2033862, encodeId=edbe2033862a7, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 24 15:21:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285562, encodeId=8f3928556242, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Feb 06 07:07:17 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365638, encodeId=72c913656380b, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Feb 03 00:21:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284441, encodeId=922c284441ed, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Fri Feb 02 10:25:45 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284416, encodeId=5eef284416c4, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Feb 02 08:17:25 CST 2018, time=2018-02-02, status=1, ipAttribution=)]
    2018-02-02 1dd8c52fm63(暂无匿称)

    了解了解.学习学习

    0

相关资讯

Liver Int:孕酮受体的突变使HIV阳性的患者易感戊型肝炎

研究发现,孕酮的一个突变,为免疫抑制个体易感HEV感染,提供了一个研究思路。

Sci Transl Med:HIV新疗法!

艾滋病是一种危害性极大的传染病,由HIV病毒引起。HIV是一种能攻击人体免疫系统的病毒。它把人体免疫系统中最重要的CD4+T淋巴细胞作为主要攻击目标,大量破坏该细胞,使人体丧失免疫功能,导致人体易于感染各种疾病,并可发生恶性肿瘤,病死率较高。目前常用的治疗是ART干预,但效果不佳,有研究发现,或许是肠道归巢蛋白(α-4β-7)搞的鬼。

抗艾新“武器”!我国内地HIV治疗单片复方制剂上市

近日,葛兰素史克(GSK)宣布,其控股合资公司ViiV Healthcare1的以新一代整合酶抑制剂多替拉韦为核心的单片复方制剂多替阿巴拉米片在中国内地上市,这也是我国内地HIV治疗领域的首个完整治疗方案的单片复方制剂,将使HIV治疗更为方便、高效。

J Clin Invest:全新研究找到HIV“隐藏蓄水池”的秘密,或能将HIV一网打尽!

最近一项旨在消除艾滋病病毒的“踢杀”研究揭示了寻找治疗方法的潜在障碍。乔治华盛顿大学的研究人员最近的一项研究发现,潜伏的HIV蓄水池对CD8 T细胞有抵抗力,CD8 T细胞是一种白细胞,其主要功能是杀死受感染的细胞。

PLOS Medicine: Fc修饰的HIV-1人单克隆抗体-VRC01LS的安全性和药代动力学研究

背景:VRC01是人类体内一种针对HIV-1包膜糖蛋白(Env)的CD4结合位点的单克隆抗体(bnMAb),目前本研究验证了IIb期成人HIV-1预防效果。 而VRC01LS是VRC01的修改版本,其方法是通过增加对新生儿Fc受体的结合亲和力来延长血清半衰期。

PNAS:HIV新突破,血液检测成为过去,唾液检测准确率100%!

在一份最新的报告中,研究人员表示,一项基于唾液的实验性艾滋病检测显示出了希望。这项新的测试能够像血液测试一样可靠地检测出唾液中HIV抗体的早期证据。